CClinicalTrials.gg
Sign In
CompletedNCT04365218Updated Apr 21, 2022

A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease

A Phase 1 interventional study of MEDI8367 and Placebo in Chronic Kidney Disease, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-21.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2021, 5 years 9 months ago, and no results have been posted to the registry.
Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This Phase I First in Human (FIH) study is being conducted to determine the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity profile of MEDI8367 across the dose range.

Read the detailed description

This is a Phase I, FIH, randomized, blinded, placebo-controlled study, to evaluate the safety and PK of MEDI8367 as single ascending doses (SAD) in healthy subjects and as a single dose in healthy subjects of Japanese-descent and in subjects with chronic kidney disease (CKD).

Six cohorts, Cohorts 1 to 5 (healthy volunteers including Japanese subjects in Cohort 5) each consisting of 8 subjects (total 40 subjects), and Cohort 6 (subjects with CKD) consisting of 30 subjects, will participate in the study. The starting dose is dose A of MEDI8367 with up to 3 dose escalations planned (provisional doses of dose B, dose C, and dose D).

The study will comprise of:

  • A Screening Period of maximum 28 days;
  • A Treatment Period during which subjects will be resident at the Clinical Unit/non-clinical sites from the day before investigational medicinal product (IMP) administration (Day -1) until at least 72 hours after IMP administration; discharged on Day 4; and
  • A Follow-up Period (out-patient) with 8 visits; the final Follow-up Visit (Visit 10) within 90 ± 4 days after the last IMP dose. The study day for the last visit may be adjusted based on PK/PD results from the current and previous cohorts.

Dosing for Cohorts 1 to 4 and Cohort 6 will proceed with 2 subjects in a sentinel cohort, such that one subject will be randomized to receive MEDI8367 and one subject will be randomized to receive placebo. The blinded safety data from the sentinel subjects up to 3 days post-dose will be reviewed by the site Principal Investigator (PI) before the remaining subjects in the cohort are dosed. Dosing is proposed to continue based on a lack of significant safety findings in the first 2 subjects dosed per cohort. The remaining 6 subjects in Cohorts 1 to 4, respectively, and 28 subjects in Cohort 6, will be dosed at least 3 days after the sentinel cohort.

02

Conditions studied

  • Chronic Kidney Disease

Keywords

  • First-in-human, Single Ascending Dose
03

In context

Kidney Diseases

3,838 studies on the registry are indexed under Kidney Diseases; 498 are open to participants now.

This study's enrollment of 12 is below the median of 70 across 2,639 interventional studies indexed under Kidney Diseases.

Browse Kidney Diseases studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.

Of its 358 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.

Browse AstraZeneca studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Provision of signed and dated, written informed consent and any locally required authorization (eg, Health Insurance Portability and Accountability Act in the USA) prior to any study specific procedures.
  • Male and/or female subjects aged 18 to 55 years (for Cohort 6 see below), inclusive, at the Screening Visit.

  • Females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit/study site, must not be lactating and must be of non-childbearing potential, confirmed at the Screening Visit by fulfilling one of the following criteria:

    1. Postmenopausal defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and FSH levels in the postmenopausal range.
    2. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.
  • Non-sterilized male subjects who are sexually active with a female partner of childbearing potential must use a male condom with spermicide starting from the time of IMP administration until 3 months after the final Follow-up Visit. It is strongly recommended for the female partner of a male subject to also use a highly effective method of contraception throughout this period.
  • Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive, at the Screening Visit.
  • Ability and willingness to adhere to the visit/protocol schedule and complete the Follow-up Period.

The subjects in Cohort 5 (subjects of Japanese descent) must fulfil the following additional criterion:

  • Subjects must be of Japanese descent, defined as having 4 grandparents who are Japanese. This includes second and third generation subjects of Japanese descent whose parents or grandparents are living in a country other than Japan.

The subjects in Cohort 6 (subjects with CKD) must fulfil the following additional criteria:

  • Male and/or female subjects aged 18 to 70 years, inclusive, at the Screening Visit.
  • Have a BMI between 18 and 45 kg/m2 inclusive and weigh at least 50 kg and no more than 150 kg inclusive, at the Screening Visit.

  • Subjects must have CKD, defined as:

    1. An estimated glomerular filtration rate (eGFR) 30 to 89 mL/min/1.73 m2 based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, and
    2. Macroalbuminuria, defined as 300-3000 mg albumin/g creatinine based on the spot urine sample collected at the Screening Visit and the geometric mean of 3 sequential first morning void urine sample s at Visit 2 (Day 1).

  • Stable BP meeting all of the following criteria:

    1. BP ≤ 150/100 mmHg at the Screening Visit and Visit 2 (Day -1).
    2. A stable dose of Angiotensin converting enzyme inhibitors (ACEi) or Angiotensin receptor blockers (ARB) for at least 4 weeks prior to the Screening Visit, per the local/site guidelines. Subjects who have been deemed unable to tolerate ACEi or ARB therapy due to allergy or complications may be enrolled. Dose adjustment of the next/previous titration dose within 2 weeks of the Screening Visit is acceptable.
    3. A stable dose of any other antihypertensive medication (including diuretic therapy) for at least 4 weeks prior to the Screening Visit.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or condition that, in the opinion of the site PI and/or medical monitor, would place the subject at an unacceptable risk to participate in this study or interfere with evaluation of the investigational product or interpretation of subject safety or study results, including, but not limited to:

    1. History of any blood brain barrier (BBB) breakdown such as, but not limited to, recent traumatic brain/spinal injury, multiple sclerosis, active central nervous system vasculitis, recent stroke or cerebral hemorrhage, neurosurgery, meningoencephalitis, active or uncontrolled seizures, or lumbar puncture within the preceding 6 months.
    2. Prior malignancy other than non-melanoma skin cancer or cervical cancer in situ treated with apparent success with curative therapy (response duration of > 5 years).
    3. Subjects with renal allografts.
  • Proliferative retinopathy confirmed by retinal imaging at the Screening Visit
  • History or presence of hematological, hepatic or renal disease (except Cohort 6) or any other condition known to interfere with administration, absorption, distribution, metabolism or excretion of drugs.
  • Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IMP.
  • Any clinically relevant abnormal findings in physical examination, vital signs, hematology, clinical chemistry, or urinalysis during screening or Day -1 that, in the opinion of the site PI or medical monitor, may compromise the safety of the subject in the study, interfere with the evaluation of the IMP, or reduce the subjects' ability to participate in the study.

Note: Abnormal urinary findings will not exclude subjects in Cohort 6.

  • Any laboratory values with the following deviations at screening or admission (for Cohort 6 see below):

    1. ALT > Upper limit of normal (ULN).
    2. AST > ULN.
    3. Total bilirubin (TBL) > ULN (unless due to Gilbert's syndrome).
    4. Creatinine > ULN.
    5. WBC count \< lower limit of normal (LLN).
    6. Hb \< LLN.
    7. Impaired renal function, defined as eGFR \< 90 mL/min/1.73 m2 based on the CKD-EPI equation.
  • Any positive result at the Screening Visit for serum hepatitis B surface antigen (HBsAg), hepatitis C antibody and human immunodeficiency virus (HIV).

  • Abnormal vital signs at Screening or Visit 2 (Day -1), after 10 minutes supine rest, defined as any of the following:

    1. SBP \< 90 mmHg or ≥ 140 mmHg.
    2. DBP \< 50 mmHg or ≥ 90 mmHg.
    3. HR \< 45 or > 85 beats per minute (bpm).

  • Any clinically important abnormalities in rhythm, conduction or morphology of the resting 12-lead ECG as considered by the site PI that may interfere with the interpretation of QTc interval changes, including abnormal ST-T-wave morphology or left ventricular hypertrophy, at screening or admission.

    1. Prolonged QTcF > 450 ms.
    2. Family history of long QT syndrome.
    3. PR (PQ) interval shortening \< 120 ms (PR > 110 ms but \< 120 ms is acceptable if there is no evidence of ventricular pre-excitation).
    4. PR (PQ) interval prolongation (> 240 ms) intermittent second (Wenckebach block while asleep is not exclusive) or third degree atrioventricular (AV) block, or AV dissociation.
    5. Persistent or intermittent complete bundle branch block (BBB), incomplete bundle branch block (IBBB), or intraventricular conduction delay (IVCD) with QRS > 110 ms. Subjects with QRS > 110 ms but \< 120 ms are acceptable if there is no evidence of e.g., ventricular hypertrophy or pre-excitation.
  • Known or suspected history of drug abuse as judged by the site PI.
  • History of alcohol and/or substance abuse within the last 6 months or excessive intake of alcohol as judged by the site PI.
  • Positive screen for drugs of abuse, including recreational marijuana, at the Screening Visit or upon admission to the Clinical Unit/study. Subjects who utilize benzodiazepines for chronic anxiety or sleep disorders may be permitted to enter the study.

  • History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the site PI or history of hypersensitivity to drugs with a similar chemical structure or class to MEDI8367.

    1. History of severe allergic reaction requiring hospitalization or,
    2. History of severe reaction to any medication including biologic agents or human gamma globulin therapy or,
    3. History of allergy or reaction to any component of the IMP formulation.

  • Use of any prescribed or nonprescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, mega-dose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals with the 2 weeks or 5 half-lives prior to the first administration of IMP (Day 1) (whichever is longer). Further clarification regarding specific medications is provided below:

    1. Female subjects will be allowed to take hormone replacement therapy.
    2. Current or previous use of systemic corticosteroids within 60 days prior to Day 1 is prohibited
    3. Topical, intra-articular, nasal, inhaled, and ophthalmic corticosteroids are permitted.
    4. Antiplatelet therapy (i.e., aspirin, clopidogrel [Plavix], ticagrelor [Brilinta], or prasugrel), anticoagulation therapy (i.e., warfarin, factor Xa inhibitors, direct thrombin inhibitors, or heparin), and thrombolytic use, in the past month prior to Day 1 or planned use during the duration of the study, are prohibited.
  • Plasma donation within one month of the Screening Visit or any blood donation/blood loss > 500 mL during the 3 months prior to Day 1 (or > 1200 mL in the year prior to Day 1).
  • Has received another new chemical or biologic entity (defined as a compound which has not been approved for marketing) within 4 months or 5 half-lives prior to the Screening Visit (whichever is longer), or planned participation in such a study prior to the end of the follow-up period.

Note: subjects consented and screened, but not randomized in this study or a previous phase I study, are not excluded.

  • Scheduled surgery, including dental surgery, within 8 weeks of the scheduled completion date of the study.
  • Involvement of any AstraZeneca, Clinical Unit, Contract Research Organization (CRO), or study site employee or their close relatives, regardless of the employee's role.
  • Judgement by the site PI that the subject should not participate in the study if they have any ongoing or recent (i.e., during the Screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.
  • Subjects who cannot communicate reliably with the site PI.
  • Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.

The following exclusion criteria apply to subjects in Cohort 6 (subjects with CKD):

  • Clinically significant late diabetic complications, including symptoms consistent with angina, congestive heart failure, and peripheral arterial disease (claudication), or other complications such as proliferative retinopathy, maculopathy, or gastroparesis.
  • Chronic kidney disease due to abnormal anatomy of the urinary system or autosomal dominant polycystic kidney disease (ADPKD).
  • Aggressive or serious neuropathies, in particular immune related demyelinating neuropathies such as Guillain-Barré, or one of its variants.

  • Any laboratory values with the following deviations at screening or admission:

    1. ALT > 2 x ULN.
    2. AST > 2 x ULN.
    3. TBL > ULN (unless due to Gilbert's syndrome).
    4. Hb \<100 g/L
    5. Glycated hemoglobin (HbA1C) > 10.5% measured at the Screening Visit.

  • Use of any prescribed or nonprescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, mega-dose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals with the 2 weeks or 5 half-lives prior to the first administration of IMP (Day 1) (whichever is longer). Further clarification regarding specific medications is provided below:

    1. Subjects may take their usual prescribed medication, or any other medication taken on the advice of their physician with the exception of systemic corticosteroids. They should have been on a stable drug regimen with no changes in agents or doses for at least 4 weeks prior to participation in the study. Dose adjustment of the next/previous titration dose within 2 weeks of the Screening Visit is acceptable.
    2. Any serum creatinine-altering drugs within 1 month prior to the Screening Visit including but not limited to amphotericin, cimetidine, clofibrate, dronedarone, ketoconazole, probenecid, ranolazine, trimethoprim, aminoglycosides, or cephalosporins are prohibited.
    3. Use of insulin is prohibited.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Cohort 1 (Dose A)

    6 subjects will be randomized to receive MEDI8367 Dose A and 2 subjects will be randomized to receive placebo.

    Drug: MEDI8367 · Drug: Placebo

  • Experimental
    Cohort 2 (Dose B)

    6 subjects will be randomized to receive MEDI8367 Dose B and 2 subjects will be randomized to receive placebo.

    Drug: MEDI8367 · Drug: Placebo

  • Experimental
    Cohort 3 (Dose C)

    6 subjects will be randomized to receive MEDI8367 Dose C and 2 subjects will be randomized to receive placebo.

    Drug: MEDI8367 · Drug: Placebo

  • Experimental
    Cohort 4 (Dose D)

    6 subjects will be randomized to receive MEDI8367 Dose D and 2 subjects will be randomized to receive placebo.

    Drug: MEDI8367 · Drug: Placebo

  • Experimental
    Cohort 5 (Dose D)

    6 subjects will be randomized to receive MEDI8367 Dose D or the highest tolerable dose based on Cohorts 1 to 4 and 2 subjects will be randomized to receive placebo.

    Drug: MEDI8367 · Drug: Placebo

  • Experimental
    Cohort 6 (Dose D)

    15 subjects will be randomized to receive MEDI8367 Dose D or the highest tolerable dose based on Cohorts 1 to 4 and 15 subjects will be randomized to receive placebo.

    Drug: MEDI8367 · Drug: Placebo

Interventions

  • DrugMEDI8367

    Subjects will receive subcutaneous (SC) single dose of MEDI8367, depending upon dose escalation strategy and Safety Review Committee results. The maximum dose will not exceed 600 mg. The dose will be administered as a single injection or multiple injections in the abdomen region.

  • DrugPlacebo

    Saline solution for injection and the placebo volume to be administered will be equivalent to the MEDI8367 volume administered for each dosing cohort.

06

What researchers measure

Primary outcomes

  1. Number of subjects with adverse events (AEs) and serious adverse events (SAEs)

    To assess AEs as a variable of safety and tolerability of SC of MEDI8367

    Time frame: From screening (Day -28) to follow-up period (Day 90 ± 4 days)

  2. Number of subjects with abnormal systolic blood pressure (SBP)

    To assess supine position SBP as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28) up to follow-up period (Day 90 ± 4 days)

  3. Number of patients with abnormal diastolic blood pressure (DBP)

    To assess supine position DBP as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28) up to follow-up period (Day 90 ± 4 days)

  4. Number of subjects with abnormal HR

    To assess change in supine position HR as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28) up to follow-up period (Day 90 ± 4 days)

  5. Number of subjects with respiratory rate

    To assess change in supine position respiratory rate as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28) up to follow-up period (Day 90 ± 4 days)

  6. Number of subjects with abnormal oral body temperature

    To assess change in oral body temperature as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28) up to follow-up period (Day 90 ± 4 days)

  7. Number of subjects with abnormal electrocardiogram (ECG)

    To assess electrical activity changes in ECG as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28) up to follow-up period (Day 90 ± 4 days)

  8. Number of subjects with abnormal physical examination

    To assess change in physical examination as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28) up to follow-up period (Day 90 ± 4 days)

  9. Number of subjects with abnormal structured neurological assessment

    To assess change in structured neurological assessment as safety and tolerability of MEDI8367. Any new or aggravated clinically relevant abnormal neurological examination finding compared to the baseline assessment will be reported as an AE

    Time frame: From screening (Day -28 ) up to follow-up period (Day 90 ± 4 days)

  10. Number of subjets with abnormal retinal imaging

    To assess retinal imaging as a variable of safety and tolerability of MEDI8367. The presence of proliferative retinopathy or any other new retinal changes will be recorded. Any new or aggravated clinically relevant abnormal retinal imaging finding compared to the baseline assessment will be reported as an AE

    Time frame: From screening (Day -28) up to follow-up period (Day 90 ± 4 days)

  11. Number of subjects with abnormal Hemoglobin (Hb) level

    To assess change in Hb as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  12. Number of subjects with abnormal red blood cells (RBC) count

    To assess RBC count as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  13. Number of subjects with abnormal white blood cells (WBC) count

    To assess WBC count as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  14. Number of subjects with abnormal differential WBC count

    To assess differential WBC count as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  15. Number of subjects with abnormal hematocrit (HCT)

    To assess HCT as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  16. Number of subjects with abnormal mean corpuscular volume (MCV)

    To assess MCV as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  17. Number of subjects with abnormal mean corpuscular hemoglobin (MCH)

    To assess MCH as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  18. Number of subjects with abnormal reticulocytes absolute count

    To assess reticulocytes absolute count as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  19. Number of subjects with abnormal mean corpuscular hemoglobin concentration (MCHC)

    To assess MCHC as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  20. Number of subjects with abnormal platelets count

    To assess platelets count as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  21. Number of subjects with abnormal creatinine level

    To assess creatinine level as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  22. Number of subjects with abnormal blood urea nitrogen level

    To assess blood urea nitrogen level as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  23. Number of subjects with abnormal urea level.

    To asses urea level as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  24. Number of subjects with abnormal bicarbonate level

    To asses bicarbonate level as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  25. Number of subjects with abnormal creatine kinase (CK) level

    To asses CK level as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  26. Number of subjects with abnormal follicle stimulating hormone (FSH)/luteinizing hormone (LH) level

    To asses FSH/LH level for postmenopausal females as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28) to treatment period (Day -1)

  27. Number of subjects with abnormal C-reactive protein (CRP) level

    To asses CRP level as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  28. Number of subjects with abnormal cystatin C level

    To asses cystatin C level in Cohort 6 only (subjects with CKD) as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  29. Number of subjects with abnormal glucose (fasting) level

    To asses glucose (fasting) level as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  30. Number of subjects with abnormal potassium level

    To assess potassium level as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  31. Number of subjects with abnormal sodium level

    To assess sodium level as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  32. Number of subjects with abnormal phosphate level

    To assess phosphate level as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  33. Number of subjects with abnormal calcium level

    To assess calcium level as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  34. Number of subjects with abnormal chloride level

    To assess chloride level as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  35. Number of subjects with abnormal alkaline phosphatase (ALP)

    To assess ALP level as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  36. Number of subjects with abnormal bilirubin level

    To assess bilirubin level as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  37. Number of subjects with abnormal alanine aminotransferase (ALT)

    To assess ALT as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  38. Number of subjects with abnormal aspartate aminotransferase (AST)

    To assess AST as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  39. Number of subjects with abnormal albumin level

    To assess albumin level as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  40. Number of subjects with abnormal urine protein level

    To assess change in urine protein as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  41. Number of subjects with abnormal urine glucose level

    To assess changes in abnormal urine glucose as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  42. Number of subjects with abnormal urine pH

    To assess change in urine pH as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  43. Number of subjects with abnormal urine ketone level

    To assess change in urine ketone as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  44. Number of subjects with abnormal urine bilirubin level

    To assess change in urine bilirubin as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  45. Number of subjects with abnormal urine blood level

    To assess change in urine blood as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  46. Number of subjects with abnormal urine color.

    To assess change in urine color as a variable of safety and tolerability of MEDI8367 following SC administration of SAD.

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  47. Number of subjects with abnormal urine appearance.

    To assess change in urine apperance as a variable of safety and tolerability of MEDI8367 following SC administration of SAD.

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  48. Number of subjects with abnormal urine specific gravity level

    To assess change in urine specific gravity as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  49. Number of subjects with abnormal urine leukocyte esterase level

    To assess change in urine leukocyte esterase as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  50. Number of subjects with abnormal urine urobilinogen level

    To assess change in urine urobilinogen as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  51. Number of subjects with abnormal urine nitrite level

    To assess change in urine nitrite as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  52. Number of subjects with abnormal urine RBC level

    To assess change in urine microscopy included RBC as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  53. Number of subjects with abnormal urine WBC level

    To assess change in urine microscopy included WBC as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

  54. Number of subjects with abnormal urine casts level

    To assess change in urine microscopy casts as a variable of safety and tolerability of MEDI8367

    Time frame: From screening (Day -28 to Day -2) through follow-up period (up to Day 90 ± 4 days)

Secondary outcomes

  1. Plasma PK analysis: Maximum observed serum drug concentration (Cmax)

    To assess Cmax of MEDI8367 following SC administration of SAD

    Time frame: From treatment period (Day 1) to follow-up period (up to Day 90 ± 4 days)

  2. Plasma PK analysis: Time to reach maximum observed concentration (tmax)

    To assess tmax of MEDI8367 following SC administration of SAD

    Time frame: From treatment period (Day 1) to follow-up period (up to Day 90 ± 4 days)

  3. Plasma PK analysis: Terminal half-life (t½)

    To assess t½ of MEDI8367 following SC administration of SAD

    Time frame: From treatment period (Day 1) to follow-up period (up to Day 90 ± 4 days)

  4. Plasma PK analysis: Area under the plasma concentration-time curve from zero to the last quantifiable concentration (AUClast)

    To assess AUClast of MEDI8367 following SC administration of SAD

    Time frame: From treatment period (Day 1) to follow-up period (up to Day 90 ± 4 days)

  5. Plasma PK analysis: Area under plasma concentration-time curve from zero to infinity (AUCinf)

    To assess AUCinf of MEDI8367 following SC administration of SAD

    Time frame: From treatment period (Day 1) to follow-up period (up to Day 90 ± 4 days)

  6. Plasma PK analysis: Apparent total body clearance of drug from serum after extravascular administration (CL/F)

    To assess CL/F of MEDI8367 following SC administration of SAD

    Time frame: From treatment period (Day 1) to follow-up period (up to Day 90 ± 4 days)

  7. Plasma PK analysis: Volume of distribution (apparent) following extravascular administration (based on terminal phase; Vz/F)

    To assess Vz/F of MEDI8367 following SC administration of SAD

    Time frame: From treatment period (Day 1) to follow-up period (up to Day 90 ± 4 days)

  8. Plasma PK analysis: Volume of distribution (apparent) at steady state following extravascular administration (Vss/F)

    To assess Vss/F of MEDI8367 following SC administration of SAD

    Time frame: From treatment period (Day 1) to follow-up period (up to Day 90 ± 4 days)

  9. Plasma PK analysis: Area under plasma concentration-time curve from zero to the last quantifiable concentration divided by the dose administered (AUClast/D)

    To assess AUClast/D of MEDI8367 following SC administration of SAD

    Time frame: From treatment period (Day 1) to follow-up period (up to Day 90 ± 4 days)

  10. Plasma PK analysis: Area under plasma concentration-time curve from zero to infinity divided by the dose administered (AUCinf/D)

    To assess AUCinf/D of MEDI8367 following SC administration of SAD

    Time frame: From treatment period (Day 1) to follow-up period (up to Day 90 ± 4 days)

  11. Plasma PK analysis: Maximum observed serum drug concentration divided by the dose administered (Cmax/D).

    To assess Cmax/D of MEDI8367 following SC administration of SAD.

    Time frame: From treatment period (Day 1) to follow-up period (up to Day 90 ± 4 days)

  12. Immunogenecity: ADA titer

    To assess ADA titer of MEDI8367 following SC administration of SAD

    Time frame: From treatment period (Day 1) to follow-up period (up to Day 90 ± 4 days)

  13. Immunogenecity: Anti-drug antibody (ADA) incidence.

    To assess ADA incidence of MEDI8367 following SC administration of SAD.

    Time frame: From treatment period (Day 1) to follow-up period (up to Day 90 ± 4 days)

07

Study locations

1 site
  • Research Site
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04365218
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Apr 28, 2020
Start date
Jul 22, 2020
Primary completion
Jan 3, 2021
Completion
Jan 3, 2021
Last update
Apr 21, 2022

Study contacts

Dr David Han, MD
principal investigator · PAREXEL Early Phase Clinical Unit-Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Kidney Diseases→

Other studies from this sponsor

AstraZeneca→

Start the discussion